Carmine N. Stengone - CEO and President, Director at Contineum Therapeutics, Inc.

Insider Transactions and Holdings

Entity Type
Individual
Role
CEO and President, Director
Issuer Symbol
CTNM on Nasdaq
All Insider Reports
All Insider Reports

Carmine N. Stengone - trading volume in the past year for Contineum Therapeutics, Inc.

Holdings reported by Carmine N. Stengone for Contineum Therapeutics, Inc.

Security Num Shares Value Price $ Transaction Date Ownership Underlying Class Underlying Amount
Class A Common Stock 14,954 $239,264 $16.00 11 Feb 2026 Direct
Stock Option (right to buy) 128,017 11 Feb 2026 Direct Class A Common Stock

Transactions reported by Carmine N. Stengone for Contineum Therapeutics, Inc.

Sym Class Transaction % Value $ * Price $ Shares Shares After Date Ownership
* An asterisk sign (*) next to the price indicates that the price is likely invalid.